OrthoPediatrics Corp. (NASDAQ:KIDS) Short Interest Update

OrthoPediatrics Corp. (NASDAQ:KIDS) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,040,000 shares, a growth of 10.5% from the March 15th total of 941,200 shares. Based on an average daily volume of 179,900 shares, the short-interest ratio is currently 5.8 days. Approximately 6.6% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Truist Financial lowered OrthoPediatrics from a “buy” rating to a “hold” rating and reduced their target price for the company from $39.00 to $31.00 in a research note on Thursday, January 25th. Needham & Company LLC reissued a “buy” rating and set a $37.00 price target on shares of OrthoPediatrics in a research note on Wednesday, April 10th. Finally, JMP Securities reissued a “market outperform” rating and set a $50.00 price target on shares of OrthoPediatrics in a research note on Thursday, March 7th.

Insiders Place Their Bets

In other OrthoPediatrics news, insider Joseph W. Hauser sold 2,903 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $28.06, for a total transaction of $81,458.18. Following the transaction, the insider now owns 52,858 shares in the company, valued at approximately $1,483,195.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other OrthoPediatrics news, insider Joseph W. Hauser sold 2,903 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $28.06, for a total transaction of $81,458.18. Following the transaction, the insider now owns 52,858 shares in the company, valued at approximately $1,483,195.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 2,741 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $75,624.19. Following the completion of the sale, the general counsel now owns 52,403 shares in the company, valued at approximately $1,445,798.77. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,253 shares of company stock worth $477,375. Company insiders own 32.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Legal & General Group Plc raised its position in shares of OrthoPediatrics by 5.0% in the 2nd quarter. Legal & General Group Plc now owns 4,878 shares of the company’s stock worth $210,000 after buying an additional 233 shares during the period. State of Wyoming raised its position in shares of OrthoPediatrics by 23.1% in the 4th quarter. State of Wyoming now owns 1,380 shares of the company’s stock worth $55,000 after buying an additional 259 shares during the period. Swiss National Bank raised its position in shares of OrthoPediatrics by 0.9% in the 1st quarter. Swiss National Bank now owns 34,600 shares of the company’s stock worth $1,532,000 after buying an additional 300 shares during the period. FMR LLC increased its holdings in OrthoPediatrics by 71.7% in the 1st quarter. FMR LLC now owns 874 shares of the company’s stock valued at $39,000 after purchasing an additional 365 shares in the last quarter. Finally, HighTower Advisors LLC increased its holdings in OrthoPediatrics by 3.5% in the 1st quarter. HighTower Advisors LLC now owns 11,874 shares of the company’s stock valued at $643,000 after purchasing an additional 400 shares in the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Trading Down 2.1 %

Shares of OrthoPediatrics stock opened at $30.45 on Tuesday. OrthoPediatrics has a fifty-two week low of $23.10 and a fifty-two week high of $53.50. The firm has a market cap of $724.28 million, a PE ratio of -33.10 and a beta of 1.16. The business’s fifty day moving average is $28.02 and its two-hundred day moving average is $28.67. The company has a quick ratio of 2.90, a current ratio of 5.44 and a debt-to-equity ratio of 0.03.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Wednesday, March 6th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. The business had revenue of $37.61 million for the quarter, compared to analyst estimates of $37.59 million. OrthoPediatrics had a negative return on equity of 5.03% and a negative net margin of 14.10%. Analysts anticipate that OrthoPediatrics will post -1.34 earnings per share for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.